Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

The microalga Volvox carteri as a cell supportive building block for tissue engineering.

Stricher M., Vigneron P., Delbecq F., Sarde CO., Egles C.

Animal Study on Chronic Inflammation, published in Mater Today Bio (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mater Today Bio (2024)
Country
England
Reported sample size
—
Source database
PubMed
PMID
38464496
DOI
10.1016/j.mtbio.2024.101013

Abstract (original English)

Abstract Background V. carteri f. nagariensis constitutes, in its most simplified form, a cellularized spheroid built around and stabilised by a form of primitive extracellular matrix (ECM). Methods Based on its structure and its ability to support surface cell adhesion most likely induced by the composition of its algal ECM, we have developed a modular approach to soft tissue engineering by compact-stacking of V. carteri –based living building blocks. Results A primary biocompatibility assessment demonstrated the algal suspension cytocompatibility, its histogenesis promoting properties, and that it did not induce an inflammatory response in vitro . These results allowed us to consider the use of such algal suspension for soft tissue augmentation and to initiate the study of its in vivo biocompatibility. V. carteri exhibited cellular fate-directing properties, causing fibroblasts to take on an alkaline phosphatase + stem-cell-like phenotype and both human adipose-derived stem cells and mouse embryonic stem cells to differentiate into preadipocytes to adipocytes. The ability of V. carteri to support histogenesis and adipogenesis was also observed in vivo by subcutaneous tissue augmentation of athymic mice, highlighting the potential of V. carteri to support or influence tissue regeneration. Conclusions Our conclusion present for the first time V. carteri as an innovative and ins

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research